BRAF and melanoma: A recent phase III clinical trial (NCT02224781) reported that the treatment of nivolumab plus ipilimumab followed by dabrafenib plus trametinib resulted in a higher 2-year OS (Overall Survival) rate (72% vs. 52%, respectively; p = 0.0095) than the treatment of dabrafenib plus trametinib followed by nivolumab and ipilimumab for patients with advanced BRAF(V600)-mutant melanoma [122].